Figure 2.
Survival analyses. Kaplan–Meier curves for progression-free survival (A) and overall survival (B) for all patients with locoregional recurrent HNSCC treated with radiotherapy and cetuximab (RT + Cetetuximab) or platinum-based chemotherapy and cetuximab (CT + Cetuximab). One patient treated with CT + Cetuximab was excluded due to missing follow up.